Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
复制标题
DOI：
10.1016/j.canlet.2009.08.012
复制
发表时间：
2010-05-01
期刊：
影响因子：
9.7
通讯作者：
Eisenberger, Mario A.
中科院分区：
文献类型：
--
作者：
Antonarakis, Emmanuel S.;Carducci, Michael A.;Eisenberger, Mario A.
关键词：
几乎所有死于前列腺癌的患者都死于转移性去势抵抗疾病。尽管多西紫杉醇是这些患者的标准治疗方法，并与适度延长生存期有关，但转移性前列腺癌迫切需要新的治疗策略。在过去的几年里，我们对前列腺癌生长和发展的生物学和分子机制的理解取得了长足的进步，这导致了对许多新的靶向治疗的广泛临床测试。这篇综述讨论了过去5年出现的一些治疗转移性去势抵抗前列腺癌的关键药物，重点是分子靶点和临床试验设计。这些药物包括哺乳动物靶标雷帕霉素途径抑制剂、抗血管生成药物、表皮生长因子受体抑制剂、胰岛素样生长因子途径抑制剂、诱导凋亡药物、内皮素受体拮抗剂、核因子κB受体激活剂(RANK)配体抑制剂、维生素D类似物、细胞色素P17酶抑制剂、雄激素受体调节剂、表观遗传疗法、疫苗疗法和细胞毒性T淋巴细胞相关抗原-4阻断剂。
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the standard of care for these patients and is associated with a modest prolongation of survival, there is an urgent need for novel treatment strategies for metastatic prostate cancer. In the last several years, great strides have been made in our understanding of the biological and molecular mechanisms driving prostate cancer growth and progression, and this has resulted in widespread clinical testing of numerous new targeted therapies. This review discusses some of the key therapeutic agents that have emerged for the treatment of metastatic castration-resistant prostate cancer in the last 5 years, with an emphasis on both molecular targets and clinical trial design. These agents include mammalian target of rapamycin (mTOR) pathway inhibitors, anti-angiogenic drugs, epidermal growth factor receptor (EGFR) inhibitors, insulin-like growth factor (IGF) pathway inhibitors, apoptosis-inducing drugs, endothelin receptor antagonists, receptor activator of nuclear factor κB (RANK) ligand inhibitors, vitamin D analogues, cytochrome P17 enzyme inhibitors, androgen receptor modulators, epigenetic therapies, vaccine therapies, and cytotoxic T lymphocyte-associated antigen (CTLA)-4 blocking agents.
登录
查看更多内容
影响因子：
45.3
作者：
Carducci, MA;Padley, RJ;Nelson, JB
通讯作者：
Nelson, JB
DOI：
10.1084/jem.20001021
发表时间：
2002-03-04
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Blattman JN;Antia R;Sourdive DJ;Wang X;Kaech SM;Murali-Krishna K;Altman JD;Ahmed R
通讯作者：
Ahmed R
影响因子：
45.3
作者：
Canil, CM;Moore, MJ;Seymour, L
通讯作者：
Seymour, L
影响因子：
78.5
作者：
Bartlett, JB;Dredge, K;Dalgleish, AG
通讯作者：
Dalgleish, AG
影响因子：
2.1
作者：
Brown, JM;Corey, E;Vessella, RL
通讯作者：
Vessella, RL